Home » Stocks » ZYNE

Zynerba Pharmaceuticals, Inc. (ZYNE)

Stock Price: $4.41 USD -0.12 (-2.65%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $4.46 +0.05 (1.13%) Jul 30, 7:32 PM
Market Cap 181.92M
Revenue (ttm) 86,000
Net Income (ttm) -46.96M
Shares Out 40.07M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $4.41
Previous Close $4.53
Change ($) -0.12
Change (%) -2.65%
Day's Open 4.51
Day's Range 4.38 - 4.61
Day's Volume 737,649
52-Week Range 3.15 - 9.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

3 weeks ago - GlobeNewsWire

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). ...

1 month ago - Benzinga

DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

1 month ago - GlobeNewsWire

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

Other stocks mentioned: ARNA, CGC, CRDF, CRON, GRWG, HE, IIPR ...
1 month ago - Schaeffers Research

–  46.4% of shares voted, quorum not established to hold annual meeting –

1 month ago - GlobeNewsWire

DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

1 month ago - GlobeNewsWire

DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

1 month ago - GlobeNewsWire

DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

2 months ago - GlobeNewsWire

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

2 months ago - GlobeNewsWire

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

Other stocks mentioned: ACB, APDN, ARNA, CARA, CGC, CRBP, FLGC ...
2 months ago - Schaeffers Research

Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multiple ...

2 months ago - Proactive Investors

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a los...

2 months ago - Benzinga

These Reddit penny stocks are climbing today; are they worth adding to your watchlist? The post These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?

Other stocks mentioned: AKBA, HTZGQ
2 months ago - PennyStocks

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivale...

2 months ago - Proactive Investors

– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 –

2 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS).  The tr...

2 months ago - Proactive Investors

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the S...

3 months ago - Proactive Investors

DEVON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

3 months ago - GlobeNewsWire

Investors looking to take their portfolios one toke over the line may wish to consider taking a look – preferably sober and without the narcotizing stimulation from the celebrated wacky weed – at the fo...

Other stocks mentioned: MJ, TAP, TAP.A, VFF, YCBD
3 months ago - Benzinga

DEVON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

3 months ago - GlobeNewsWire

DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

3 months ago - GlobeNewsWire

SAN DIEGO, March 28, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) ("Zynerba " or the "Company") against certain of...

4 months ago - PRNewsWire

While it doesn't get a lot of press, the Autism market is unfortunately a rapidly growing market opportunity. According to recent data from the CDC, roughly 2% of all kids are now diagnosed with Autism ...

Other stocks mentioned: BNGO, ISWH
4 months ago - OTC PR Wire

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...

Other stocks mentioned: ARNA, BTI, HEXO, IIPR, KERN, OGI, TLRY ...
4 months ago - Schaeffers Research

Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multiple ...

4 months ago - Proactive Investors

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) believes its operations and capital requirements to be fully funded into 2024, the company announced as part of its fourth-quarter and full-year resul...

4 months ago - Proactive Investors

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) believes its operations and capital req[uirements to be fully funded into 2024, the company announced as part of its fourth quarter and full-year results publis...

4 months ago - Proactive Investors

DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

4 months ago - GlobeNewsWire

Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.

4 months ago - Zacks Investment Research

DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

4 months ago - GlobeNewsWire

Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.

5 months ago - Zacks Investment Research

ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon. The post ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today appeared first on...

5 months ago - InvestorPlace

DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

6 months ago - GlobeNewsWire

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -

7 months ago - GlobeNewsWire

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. (ZYNE)

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (“Zynerba” or the “Compa...

7 months ago - Business Wire

- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 -

7 months ago - GlobeNewsWire

DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

8 months ago - GlobeNewsWire

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in th...

Other stocks mentioned: ACB, ARNA, CGC, HEXO, HUGE, KERN, OGI ...
8 months ago - Schaeffers Research

Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) consolidated net revenue of CA$67.8 million ($52.3 million) for the first quarter of fiscal 2021, being up by around CA$300,000 from the fourth quarter of fisca...

Other stocks mentioned: CGC, CNPOF
8 months ago - Benzinga

DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

8 months ago - GlobeNewsWire

Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. However, the path forward remains targeting those with methylation of the FMR1 gene. An FDA meeting is expec...

9 months ago - Seeking Alpha

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

9 months ago - GlobeNewsWire

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

9 months ago - GlobeNewsWire

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

9 months ago - GlobeNewsWire

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

9 months ago - GlobeNewsWire

Pivotal results from Phase 3 clinical trials of Zygel for the treatment of FX Syndrome didn’t meet endpoints, but a significant discovery was made.

10 months ago - Seeking Alpha

Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Making The Case For Zynerba Pharmaceuticals

10 months ago - Seeking Alpha

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ...

10 months ago - GlobeNewsWire

About ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerl... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Aug 5, 2015
CEO
Armando Anido
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
ZYNE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.63, which is an increase of 73.02% from the latest price.

Price Target
$7.63
(73.02% upside)
Analyst Consensus: Buy